A hybrid mRNA vaccine induced broadly neutralizing antibodies against Omicron and other SARS-CoV-2 variants
I‑Jung Lee, Cheng‑Pu Sun, Ping‑Yi Wu, Yu‑Hua Lan, I‑Hsuan Wang, Wen‑Chun Liu, Joyce Pei‑Yi Yuan, Yu‑Wei Chang,
Sheng‑Che Tseng, Szu‑I Tsung, Yu‑Chi Chou, Monika Kumari, Yin‑Shiou Lin, Hui‑Feng Chen, Tsung‑Yen Chen, Chih‑Chao Lin,
Chi‑Wen Chiu, Chung‑Hsuan Hsieh, Cheng‑Ying Chuang,Chao‑Min Cheng, Hsiu‑Ting Lin, Wan‑Yu Chen, Fu‑Fei Hsu,
Ming‑Hsiang Hong, Chun‑Che Liao, Chih‑Shin Chang, Jian‑Jong Liang, Hsiu‑Hua Ma, Ming‑Tsai Chiang, Hsin‑Ni Liao,
Hui‑Ying Ko, Liang‑Yu Chen, Yi‑An Ko, Pei‑Yu Yu, Tzu‑Jing Yang, Po‑Cheng Chiang, Shang‑Te Hsu,
Yi‑Ling Lin, Chong‑Chou Lee, Han‑Chung Wu and Mi‑Hua Tao
This paper was published in the Journal of Biomedical Science on Jul. 14, 2022
Wuhan wild-type strain-based vaccines became almost ineffective against new SARS-CoV-2 variants. Academia Sinica mRNA Alpha team constructed a hybrid mRNA vaccine containing mutations of Omicron and Delta variants. When used as a booster in mice previously immunized with wild-type vaccine, the hybrid vaccine induced high titers of broadly neutralizing antibodies against all tested variants, as well as T cell responses against conserved T cell epitope. This hybrid vaccine also includes important mutation sites of Omicron BA.4/5, its effectiveness against the new dominant strains is being explored.
*Article Link: https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-022-00830-1
*The co-first authors, I-Jung Lee is a Ph.D. student of Graduate Institute of Microbiology, National Taiwan University, Cheng-Pu Sun is Project Research Manager, and Ping-Yi Wu is Senior Research Assistant of Institute of Biomedical Sciences, Academia Sinica.
*This study was conducted at the Institute of Biomedical Sciences and the Biomedical Translation Research Center, Academia Sinica.
